Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral Prophylaxis for HIV-1 Prevention among Heterosexual Men and Women. N Engl J Med. 2012;367(5):399–410.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.

Article  PubMed  Google Scholar 

Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New Engl J Med. 2010;363(27):2587–99. https://doi.org/10.1056/NEJMoa1011205.

Article  CAS  PubMed  Google Scholar 

Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. New Engl J Med. 2012;367(5):423–34. https://doi.org/10.1056/NEJMoa1110711.

Article  CAS  PubMed  Google Scholar 

Antiretroviral TS. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. World Health Organization. 2015 [cited 2023 Aug 2]; Available from: https://www.who.int/publications/i/item/9789241509565

Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir exposure and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151ra125.

Article  PubMed  PubMed Central  Google Scholar 

Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African Women. New Engl J Med. 2015;372(6):509–18. https://doi.org/10.1056/nejmoa1402269.

Article  PubMed  Google Scholar 

Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure Prophylaxis for HIV Infection among African Women. New Engl J Med. 2012;367(5):411–22. https://doi.org/10.1056/nejmoa1202614.

Article  PubMed  Google Scholar 

Van Der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012 [Internet]: [cited 2023 Feb 26]; 26(7). Available from: https://journals.lww.com/aidsonline/Fulltext/2012/04240/Unraveling_the_divergent_results_of_pre_exposure.1.aspx

Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011 [Internet]: [cited 2022 Apr 10];3(112). Available from: https://pubmed.ncbi.nlm.nih.gov/22158861/

Cottrell ML, Yang KH, Prince HMA, Sykes C, White N, Malone S, et al. A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine. J Infect Dis. 2016;214(1):55–64. https://doi.org/10.1093/infdis/jiw077.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Best BM, Burchett S, Li H, Stek A, Hu C, Wang J, et al. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med. 2015;16(8):502–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.

Article  PubMed  Google Scholar 

Covidence. Covidence - Better systematic review management. Melbourne, Victoria, Australia: Covidence (2018). [Internet]. [cited 2023 Aug 2]. Available from: https://www.covidence.org/

Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito C, et al. MTN-001: Randomized Pharmacokinetic Cross-Over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other Compartments. [cited 2022 Oct 22]; Available from: https://pubmed.ncbi.nlm.nih.gov/23383037/

Stranix-Chibanda L, Anderson PL, Kacanek D, Hosek S, Huang S, Nematadzira TG, et al. Tenofovir diphosphate concentrations in dried blood spots from pregnant and postpartum adolescent and young women receiving daily observed pre-exposure prophylaxis in Sub-Saharan Africa. Clin Infect Dis. 2021;73(7):e1893–900.

Article  CAS  PubMed  Google Scholar 

Pre-Exposure Prophylaxis Dosing in Pregnancy to Optimize HIV Prevention (PREP-P) - Full Text View - ClinicalTrials.gov. [Internet]: [cited 2023 Aug 4]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT03834909

Pharmacokinetic Study Comparing TAF and TDF as PrEP in Pregnant and Postpartum Women in South Africa - CROI Conference. [Internet]: [cited 2024 Apr 29]. Available from: https://www.croiconference.org/abstract/pharmacokinetic-study-comparing-taf-and-tdf-as-prep-in-pregnant-and-postpartum-women-in-south-africa/

Adherence Benchmarks for TFV-DP in DBS and PBMCs for African Women Using FTC/TDF PrEP - CROI Conference. [Internet]: [cited 2024 Apr 29]. Available from: https://www.croiconference.org/abstract/adherence-benchmarks-for-tfv-dp-in-dbs-and-pbmcs-for-african-women-using-ftc-tdf-prep/

Castillo-Mancilla JR, Zheng JH, Rower JE, Meditz A, Gardner EM, Predhomme J, et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013;29(2):384–90. https://doi.org/10.1089/aid.2012.0089.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.

Article  PubMed  PubMed Central  Google Scholar 

Liu AY, Yang Q, Huang Y, Bacchetti P, Anderson PL, Jin C, et al. Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for Pre-Exposure Prophylaxis (PrEP). PLoS One. 2014;9(1):e83736. https://doi.org/10.1371/journal.pone.0083736.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seifert SM, Chen X, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, et al. Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State. AIDS Res Hum Retroviruses. 2016;32(10–11):981–91. https://doi.org/10.1089/aid.2016.0008.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hendrix CW, Andrade A, Bumpus NN, Kashuba AD, Marzinke MA, Moore A, et al. Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retroviruses. 2016;32(1):32–43. https://doi.org/10.1089/aid.2015.0182.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anderson PL, Liu AY, Castillo-Mancilla JR, Gardner EM, Seifert SM, McHugh C, et al. Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy. Antimicrob Agents Chemother. 2018;62(1):1710–27. https://doi.org/10.1128/aac.01710-17.

Article  CAS  Google Scholar 

Niu X, Kubiak RW, Siriprakaisil O, Klinbuyaem V, Sukrakanchana PO, Cressey R, et al. Tenofovir-Diphosphate in Dried Blood Spots vs Tenofovir in Urine/Plasma for Oral Preexposure Prophylaxis Adherence Monitoring. 2022 [cited 2022 Oct 15]; Available from: https://doi.org/10.1093/ofid/ofac405

Drain PK, Kubiak RW, Siriprakaisil O, Klinbuayaem V, Quame-Amaglo J, Sukrakanchana P, et al. Urine tenofovir concentrations correlate with plasma and relate to tenofovir disoproxil fumarate adherence: a randomized, directly observed pharmacokinetic trial (TARGET Study). Clin Infect Dis. 2020;70(10):2143–51.

Article  CAS  PubMed  Google Scholar 

Yager JL, Brooks KM, Castillo-Mancilla JR, Nemkov C, Morrow M, Peterson S, et al. Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate. AIDS. 2021;35(15):2481–7.

Article  CAS  PubMed  Google Scholar 

Minnis AM, Gandham S, Richardson BA, Guddera V, Chen BA, Salata R, et al. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav. 2013;17(2):737.

Article  PubMed  PubMed Central  Google Scholar 

Garcia-Cremades M, Vuč Icévićicévić K, Hendrix CW, Jayachandran P, Jarlsberg L, Grant R, et al. Characterizing HIV-preventive, plasma tenofovir concentrations—A pooled participant-level data analysis from human immunodeficiency virus preexposure prophylaxis clinical trials. Clin Infect Dis. 2022;75(11):1873–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66(3):340.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anderson PL, Marzinke MA, Glidden D V, Anderson PL. Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Preexposure Prophylaxis Among Cisgender Women. [cited 2023 Feb 25]; Available from: https://doi.org/10.1093/cid/ciad021

Zhang L, Iannuzzi S, Chaturvedula A, Irungu E, Haberer JE, Hendrix CW, et al. Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women. Nat Med. 2023 [Internet] [cited 2024 Jan 8]; Available from: https://www.nature.com/articles/s41591-023-02615-x

Moore M, Stansfield S, Donnell DJ, Boily MC, Mitchell KM, Anderson PL, et al. Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence. Nat Med. 2023 [Internet] [cited 2024 Jan 8]; Available from: https://pubmed.ncbi.nlm.nih.gov/37798438/

Marrazzo J, Tao L, Becker M, Leech AA, Taylor AW, Ussery F, et al. HIV preexposure prophylaxis with emtricitabine and tenofovir disoproxil fumarate among Cisgender Women. JAMA. 2024;331(11):930–7.

Article  CAS  PubMed